Publication | Closed Access

Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial

UrologyHepatologyMedicineFirst-line TreatmentPharmacotherapyLiver CancerPenpulimab Versus SorafenibCancer TreatmentOncologyRadiation OncologyHepatocellular CarcinomaPhase 3